Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC).

Fayard A, Daguenet E, Blaise D, Chevallier P, Labussière H, Berceanu A, Yakoub-Agha I, Socié G, Charbonnier A, Suarez F, Huynh A, Mercier M, Bulabois CE, Lioure B, Chantepie S, Beguin Y, Bourhis JH, Malfuson JV, Clément L, Peffault de la Tour R, Cornillon J.

Bone Marrow Transplant. 2019 Feb 15. doi: 10.1038/s41409-019-0475-7. [Epub ahead of print]

PMID:
30770870
2.

Antilymphocyte Globulin for matched sibling donor transplantation in patients with myelofibrosis.

Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis JH, Chevallier P, Cornelissen JJ, Reményi P, Maertens J, Poiré X, Craddock C, Socié G, Itälä-Remes M, Schouten HC, Marchand T, Passweg J, Blaise D, Damaj G, Ozkurt ZN, Zuckerman T, Cluzeau T, Labussière-Wallet H, Cammenga J, McLornan D, Chalandon Y, Kröger N.

Haematologica. 2019 Jan 17. pii: haematol.2018.201400. doi: 10.3324/haematol.2018.201400. [Epub ahead of print]

3.

Comparative outcomes of myeloablative and reduced-intensity conditioning allogeneic hematopoietic cell transplantation for therapy-related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation.

Lee CJ, Labopin M, Beelen D, Finke J, Blaise D, Ganser A, Itälä-Remes M, Chevallier P, Labussière-Wallet H, Maertens J, Yakoub-Agha I, Bourhis JH, Mailhol A, Mohty M, Savani BN, Nagler A.

Am J Hematol. 2018 Dec 30. doi: 10.1002/ajh.25395. [Epub ahead of print]

PMID:
30597620
4.

Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC.

Bourgeois AL, Labopin M, Leclerc M, de Latour RP, Bourhis JH, Ceballos P, Orvain C, Wallet HL, Bilger K, Blaise D, Rubio MT, Guillaume T, Mohty M, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Oncotarget. 2018 Nov 27;9(93):36603-36612. doi: 10.18632/oncotarget.26391. eCollection 2018 Nov 27.

5.

Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC.

Caulier A, Drumez E, Gauthier J, Robin M, Blaise D, Beguin Y, Michallet M, Chevallier P, Bay JO, Vigouroux S, Desbrosses Y, Cornillon J, Nguyen S, Dauriac C, de Latour RP, Lioure B, Rohrlich PS, Carré M, Bourhis JH, Huynh A, Suarez F, Garnier F, Duhamel A, Yakoub-Agha I.

Curr Res Transl Med. 2019 Feb;67(1):8-15. doi: 10.1016/j.retram.2018.08.003. Epub 2018 Sep 8.

6.

High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.

Avivi I, Arcaini L, Ferretti VV, Boumendil A, Finel H, Milone G, Zaja F, Liliana D, Musso M, Didier B, Bachy E, Wattad M, Nicolas-Virelizier E, Gramatzki M, Bourhis JH, Caillot D, Haenel A, Held G, Thieblemont C, Jindra P, Pohlreich D, Guilhot F, Kroschinsky F, Wahlin B, Scheid C, Ifrah N, Berthou C, Dreger P, Montoto S, Conconi A.

Br J Haematol. 2018 Sep;182(6):807-815. doi: 10.1111/bjh.15454. Epub 2018 Jul 9.

PMID:
29984825
7.

Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.

Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socié G, Ljungman P, Huynh A, Deconinck E, Wu D, Bourhis JH, Cahn JY, Polge E, Mohty M, Savani BN, Nagler A.

Am J Hematol. 2018 Sep;93(9):1142-1152. doi: 10.1002/ajh.25211. Epub 2018 Aug 15.

PMID:
29981272
8.

Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?

Robinson TM, Fuchs EJ, Zhang MJ, St Martin A, Labopin M, Keesler DA, Blaise D, Bashey A, Bourhis JH, Ciceri F, Ciurea SO, Devine SM, Mohty M, McCurdy SR, Milpied N, McNiece IK, Rocha V, Romee R, Socie G, Yakoub-Agha I, Soiffer RJ, Eapen M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant and the Center for International Blood and Marrow Transplant Research.

Blood Adv. 2018 Jun 12;2(11):1180-1186. doi: 10.1182/bloodadvances.2018018291.

9.

Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Salvatore D, Labopin M, Ruggeri A, Battipaglia G, Ghavamzadeh A, Ciceri F, Blaise D, Arcese W, Sociè G, Bourhis JH, Van Lint MT, Bruno B, Huynh A, Santarone S, Deconinck E, Mohty M, Nagler A.

Haematologica. 2018 Aug;103(8):1317-1328. doi: 10.3324/haematol.2018.189258. Epub 2018 May 10.

10.

Persistence of Yellow Fever Immunization-Induced Antibodies in Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Adler M, Lapierre V, Sakr R, Bourhis JH, Gachot B, Castilla-Llorente C, Wyplosz B.

J Infect Dis. 2018 May 5;217(11):1844-1845. doi: 10.1093/infdis/jiy050. No abstract available.

PMID:
29547928
11.

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.

Garderet L, Iacobelli S, Koster L, Goldschmidt H, Johansson JE, Bourhis JH, Krejci M, Leleu X, Potter M, Blaise D, Koenecke C, Peschel C, Radocha J, Metzner B, Lenain P, Schäfer-Eckart K, Pohlreich D, Grasso M, Caillot D, Einsele H, Ladetto M, Schönland S, Kröger N.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1372-1378. doi: 10.1016/j.bbmt.2018.01.035. Epub 2018 Feb 3.

PMID:
29408334
12.

Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation.

Devillier R, Labopin M, Chevallier P, Ledoux MP, Socié G, Huynh A, Bourhis JH, Cahn JY, Roth-Guepin G, Mufti G, Desmier D, Michallet M, Fegueux N, Ciceri F, Baron F, Blaise D, Nagler A, Mohty M.

Bone Marrow Transplant. 2018 Apr;53(4):431-437. doi: 10.1038/s41409-017-0043-y. Epub 2018 Jan 12.

13.

Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Decroocq J, Itzykson R, Vigouroux S, Michallet M, Yakoub-Agha I, Huynh A, Beckerich F, Suarez F, Chevallier P, Nguyen-Quoc S, Ledoux MP, Clement L, Hicheri Y, Guillerm G, Cornillon J, Contentin N, Carre M, Maillard N, Mercier M, Mohty M, Beguin Y, Bourhis JH, Charbonnier A, Dauriac C, Bay JO, Blaise D, Deconinck E, Jubert C, Raus N, Peffault de Latour R, Dhedin N.

Am J Hematol. 2018 Mar;93(3):416-423. doi: 10.1002/ajh.25004. Epub 2018 Jan 8.

14.

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.

Craddock C, Versluis J, Labopin M, Socie G, Huynh A, Deconinck E, Volin L, Milpied N, Bourhis JH, Rambaldi A, Chevallier P, Blaise D, Manz M, Vellenga E, Vekemans MC, Maertens J, Passweg J, Vyas P, Schmid C, Löwenberg B, Ossenkoppele G, Mohty M, Cornelissen JJ, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and HOVON-SAKK.

J Intern Med. 2018 Apr;283(4):371-379. doi: 10.1111/joim.12720. Epub 2018 Jan 5.

15.

[Indications and follow-up for autologous hematopoietic stem cell transplantation in autoimmune and autoinflammatory diseases: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Pugnet G, Castilla-Llorente C, Puyade M, Terriou L, Badoglio M, Deligny C, Guillaume-Jugnot P, Labeyrie C, Benzidia I, Faivre H, Lansiaux P, Marjanovic Z, Bourhis JH, Faucher C, Furst S, Huynh A, Martin T, Vermersch P, Yakoub-Agha I, Farge D.

Bull Cancer. 2017 Dec;104(12S):S169-S180. doi: 10.1016/j.bulcan.2017.06.019. Epub 2017 Nov 22. Review. French.

PMID:
29173974
16.

A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.

Saleh K, Danu A, Koscielny S, Legoupil C, Pilorge S, Castilla-Llorente C, Ghez D, Lazarovici J, Michot JM, Khalife-Saleh N, Lapierre V, Alenxandrova K, Arfi-Rouche J, Bourhis JH, Ribrag V.

Leuk Lymphoma. 2018 Nov;59(11):2580-2587. doi: 10.1080/10428194.2017.1403019. Epub 2017 Nov 22.

PMID:
29164977
17.

[Chimerism analysis after hematopoietic cell transplantation: Guidelines from the Francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].

Dubois V, Alizadeh M, Bourhis JH, Etancelin P, Farchi O, Ferrand C, Goursaud L, Mollet I, Renac V, Varlet P, Yakoub-Agha I, Bay JO.

Bull Cancer. 2017 Dec;104(12S):S59-S64. doi: 10.1016/j.bulcan.2017.08.010. Epub 2017 Nov 8. French.

PMID:
29128084
18.

Expression of CD94 by ex vivo-differentiated NK cells correlates with the in vitro and in vivo acquisition of cytotoxic features.

Hasmim M, Khalife N, Zhang Y, Doldur M, Visentin G, Terry S, Giron-Michel J, Tang R, Delhommeau F, Dulphy N, Bourhis JH, Louache F, Chouaib S.

Oncoimmunology. 2017 Jul 18;6(10):e1346763. doi: 10.1080/2162402X.2017.1346763. eCollection 2017.

19.

Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies.

Paviglianiti A, Ruggeri A, Volt F, Sanz G, Milpied N, Furst S, Esquirol A, Arcese W, Picardi A, Ferra C, Ifrah N, Bourhis JH, Raj K, von dem Borne PA, Sica S, Menard AL, Bloor A, Kenzey C, Gluckman E, Rocha V.

Br J Haematol. 2017 Dec;179(5):790-801. doi: 10.1111/bjh.14962. Epub 2017 Oct 19.

PMID:
29048109
20.

Enterocytozoon bieneusi Microsporidiosis in Stem Cell Transplant Recipients Treated with Fumagillin

Bukreyeva I, Angoulvant A, Bendib I, Gagnard JC, Bourhis JH, Dargère S, Bonhomme J, Thellier M, Gachot B, Wyplosz B.

Emerg Infect Dis. 2017 Jun;23(6):1039-1041. doi: 10.3201/eid2306.161825.

21.

Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT.

Canaani J, Labopin M, Socié G, Nihtinen A, Huynh A, Cornelissen J, Deconinck E, Gedde-Dahl T, Forcade E, Chevallier P, Bourhis JH, Blaise D, Mohty M, Nagler A.

Am J Hematol. 2017 Jul;92(7):653-659. doi: 10.1002/ajh.24737. Epub 2017 May 26.

22.

[Transfer of allogeneic stem cell transplant recipients to the intensive care unit: Guidelines from the Francophone society of marrow transplantation and cellular therapy (SFGM-TC)].

Moreau AS, Bourhis JH, Contentin N, Couturier MA, Delage J, Dumesnil C, Gandemer V, Hichri Y, Jost E, Platon L, Jourdain M, Pène F, Yakoub-Agha I.

Bull Cancer. 2016 Nov;103(11S):S220-S228. doi: 10.1016/j.bulcan.2016.09.008. Epub 2016 Nov 2. French.

PMID:
27816169
23.

Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.

Chevallier P, Labopin M, de La Tour RP, Lioure B, Bulabois CE, Huynh A, Blaise D, Turlure P, Daguindau E, Maillard N, Yakoub-Agha I, Guillerm G, Delage J, Contentin N, Bay JO, Beckerich F, Bourhis JH, Detrait M, Vigouroux S, François S, Legrand F, Guillaume T, Mohty M; SFGM-TC.

Cancer Med. 2016 Nov;5(11):3068-3076. doi: 10.1002/cam4.880. Epub 2016 Oct 17.

24.

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research.

Potter VT, Iacobelli S, van Biezen A, Maertens J, Bourhis JH, Passweg JR, Yakhoub-Agha I, Tabrizi R, Bay JO, Chevallier P, Chalandon Y, Huynh A, Cahn JY, Ljungman P, Craddock C, Lenhoff S, Russell NH, Fegueux N, Socié G, Bruno B, Meijer E, Mufti GJ, de Witte T, Robin M, Kröger N.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1615-1620. doi: 10.1016/j.bbmt.2016.05.026. Epub 2016 Jun 3.

25.

Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.

Chomel JC, Bonnet ML, Sorel N, Sloma I, Bennaceur-Griscelli A, Rea D, Legros L, Marfaing-Koka A, Bourhis JH, Ame S, Guerci-Bresler A, Rousselot P, Turhan AG.

Oncotarget. 2016 Jun 7;7(23):35293-301. doi: 10.18632/oncotarget.9182.

26.

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.

Craddock C, Labopin M, Robin M, Finke J, Chevallier P, Yakoub-Agha I, Bourhis JH, Sengelov H, Blaise D, Luft T, Hallek M, Kröger N, Nagler A, Mohty M.

Haematologica. 2016 Jul;101(7):879-83. doi: 10.3324/haematol.2015.140996. Epub 2016 Apr 14.

27.

Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin's lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).

Stamatoullas A, Brice P, Gueye MS, Mareschal S, Chevallier P, Bouabdallah R, Nguyenquoc S, Francois S, Turlure P, Ceballos P, Monjanel H, Bourhis JH, Guillerm G, Mohty M, Biron P, Cornillon J, Belhadj K, Bonmati C, Dilhuydy MS, Huynh A, Bernard M, Chrétien ML, Peffault de Latour R, Tilly H.

Bone Marrow Transplant. 2016 Jul;51(7):928-32. doi: 10.1038/bmt.2016.76. Epub 2016 Apr 4.

PMID:
27042842
28.

Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party.

Necchi A, Miceli R, Bregni M, Bokemeyer C, Berger LA, Oechsle K, Schumacher K, Kanfer E, Bourhis JH, Massard C, Laszlo D, Montoro J, Flechon A, Arpaci F, Secondino S, Wuchter P, Dreger P, Crysandt M, Worel N, Kruger W, Ringhoffer M, Unal A, Nagler A, Campos A, Wahlin A, Michieli M, Sucak G, Donnini I, Schots R, Ifrah N, Badoglio M, Martino M, Raggi D, Giannatempo P, Rosti G, Pedrazzoli P, Lanza F.

Bone Marrow Transplant. 2016 Mar;51(3):384-90. doi: 10.1038/bmt.2015.300. Epub 2015 Dec 7.

PMID:
26642334
29.

Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Mamez AC, Lévy V, Chevallier P, Blaise D, Vigouroux S, Xhaard A, Fegueux N, Contentin N, Beguin Y, Ifrah N, Bulabois CE, Suarez F, Yakoub-Agha I, Turlure P, Deconink E, Lamy T, Cahn JY, Huynh A, Maury S, Fornecker LM, Ouzegdouh M, Bay JO, Guillerm G, Maillard N, Michallet M, Malfuson JV, Bourhis JH, Rialland F, Oumedaly R, Jubert C, Leblond V, Boubaya M, Mohty M, Nguyen S.

Bone Marrow Transplant. 2016 Mar;51(3):358-64. doi: 10.1038/bmt.2015.280. Epub 2015 Nov 23.

30.

miR-181a modulates acute myeloid leukemia susceptibility to natural killer cells.

Nanbakhsh A, Visentin G, Olive D, Janji B, Mussard E, Dessen P, Meurice G, Zhang Y, Louache F, Bourhis JH, Chouaib S.

Oncoimmunology. 2015 Oct 16;4(12):e996475. eCollection 2015 Dec.

31.

Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status.

Bazarbachi A, Labopin M, Kharfan-Dabaja MA, Schwerdtfeger R, Volin L, Bourhis JH, Socié G, Daguindau E, Gedde-Dahl T, Rambaldi A, Karas M, Schlimok G, Blaise D, Chevallier P, Malard F, Schmid C, Esteve J, Nagler A, Mohty M.

Haematologica. 2016 Jan;101(1):e34-7. doi: 10.3324/haematol.2015.135681. Epub 2015 Sep 24. No abstract available.

32.

Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.

Schmid C, Labopin M, Socié G, Daguindau E, Volin L, Huynh A, Bourhis JH, Milpied N, Cornelissen J, Chevallier P, Maertens J, Jindra P, Blaise D, Lenhoff S, Ifrah N, Baron F, Ciceri F, Gorin C, Savani B, Giebel S, Polge E, Esteve J, Nagler A, Mohty M; Acute Leukemia Working Party of the European Group of Blood and Bone Marrow Transplantation.

Blood. 2015 Oct 22;126(17):2062-9. doi: 10.1182/blood-2015-06-651562. Epub 2015 Sep 8.

33.

Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer Campus.

Chamseddine AN, Willekens C, De Botton S, Bourhis JH.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S129-40. doi: 10.1016/j.clml.2015.05.001.

PMID:
26297265
34.

Monitoring antibiotic-resistant enterobacteria faecal levels is helpful in predicting antibiotic susceptibility of bacteraemia isolates in patients with haematological malignancies.

Woerther PL, Micol JB, Angebault C, Pasquier F, Pilorge S, Bourhis JH, de Botton S, Gachot B, Chachaty E.

J Med Microbiol. 2015 Jul;64(7):676-81. doi: 10.1099/jmm.0.000078. Epub 2015 May 1.

PMID:
25934549
35.

Changes in intensive care for allogeneic hematopoietic stem cell transplant recipients.

Lengliné E, Chevret S, Moreau AS, Pène F, Blot F, Bourhis JH, Buzyn A, Schlemmer B, Socié G, Azoulay E.

Bone Marrow Transplant. 2015 Jun;50(6):840-5. doi: 10.1038/bmt.2015.55. Epub 2015 Mar 23.

PMID:
25798675
36.

Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy.

Gasnault J, de Goër de Herve MG, Michot JM, Hendel-Chavez H, Seta V, Mazet AA, Croughs T, Stankoff B, Bourhis JH, Lambotte O, Delfraissy JF, Taoufik Y.

Open Forum Infect Dis. 2014 Aug 26;1(2):ofu074. doi: 10.1093/ofid/ofu074. eCollection 2014 Sep.

37.

Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.

Dhédin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, Thomas X, Chevallier P, Nguyen S, Coiteux V, Bourhis JH, Hichri Y, Escoffre-Barbe M, Reman O, Graux C, Chalandon Y, Blaise D, Schanz U, Lhéritier V, Cahn JY, Dombret H, Ifrah N; GRAALL group.

Blood. 2015 Apr 16;125(16):2486-96; quiz 2586. doi: 10.1182/blood-2014-09-599894. Epub 2015 Jan 13.

38.

Comparison of unrelated cord blood and peripheral blood stem cell transplantation in adults with myelodysplastic syndrome after reduced-intensity conditioning regimen: a collaborative study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party.

Robin M, Ruggeri A, Labopin M, Niederwieser D, Tabrizi R, Sanz G, Bourhis JH, van Biezen A, Koenecke C, Blaise D, Tischer J, Craddock C, Maillard N, Mohty M, Russel N, Schetelig J, Finke J, Gluckman E, de Witte TM, Rocha V, Kroger N.

Biol Blood Marrow Transplant. 2015 Mar;21(3):489-95. doi: 10.1016/j.bbmt.2014.11.675. Epub 2014 Dec 19.

39.

Photo quiz. Dyspnea and fever in an allogeneic stem cell recipient.

Angoulvant A, Stern JB, Wittnebel S, Bourhis JH, Gachot B, Vittecoq D, Wyplosz B.

Clin Infect Dis. 2015 Jan 1;60(1):100, 157-8. doi: 10.1093/cid/ciu839. No abstract available.

PMID:
25504499
40.

High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.

Hengeveld M, Suciu S, Chelgoum Y, Marie JP, Muus P, Lefrère F, Mandelli F, Pane F, Amadori S, Fioritoni G, Labar B, Baron F, Cermak J, Bourhis JH, Storti G, Fazi P, Hagemeijer A, Vignetti M, Willemze R, de Witte T.

Bone Marrow Transplant. 2015 Mar;50(3):341-7. doi: 10.1038/bmt.2014.262. Epub 2014 Nov 17.

41.

Enhanced cytotoxic activity of ex vivo-differentiated human natural killer cells in the presence of HOXB4.

Nanbakhsh A, Pochon C, Amsellem S, Pittari G, Tejchman A, Bourhis JH, Chouaib S.

J Immunother. 2014 Jun;37(5):278-82. doi: 10.1097/CJI.0000000000000039.

PMID:
24810639
42.

c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis.

Nanbakhsh A, Pochon C, Mallavialle A, Amsellem S, Bourhis JH, Chouaib S.

Blood. 2014 Jun 5;123(23):3585-95. doi: 10.1182/blood-2013-11-536219. Epub 2014 Mar 27.

43.

Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies.

Chouaib S, Pittari G, Nanbakhsh A, El Ayoubi H, Amsellem S, Bourhis JH, Spanholtz J.

Front Immunol. 2014 Mar 17;5:95. doi: 10.3389/fimmu.2014.00095. eCollection 2014. Review.

44.

Skin ulcers related to chronic graft-versus-host disease: clinical findings and associated morbidity.

Jachiet M, de Masson A, Peffault de Latour R, Rybojad M, Robin M, Bourhis JH, Xhaard A, Dhedin N, Sicre de Fontbrune F, Suarez F, Barete S, Parquet N, Nguyen S, Ades L, Rubio MT, Wittnebel S, Bagot M, Socié G, Bouaziz JD.

Br J Dermatol. 2014 Jul;171(1):63-8. doi: 10.1111/bjd.12828. Epub 2014 Jun 24.

PMID:
24404963
45.

Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis.

Ghez D, Micol JB, Pasquier F, Auger N, Saada V, Spentchian M, Ianotto JC, Bourhis JH, Bennaceur-Griscelli A, Terré C, Castaigne S, Rigaudeau S, Rousselot P, de Botton S.

Eur J Cancer. 2013 Nov;49(17):3666-70. doi: 10.1016/j.ejca.2013.07.147. Epub 2013 Aug 19.

PMID:
23968731
46.

Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).

Marcais A, Porcher R, Robin M, Mohty M, Michalet M, Blaise D, Tabrizi R, Clement L, Ceballos P, Daguindau E, Bilger K, Dhedin N, Lapusan S, Bay JO, Pautas C, Garban F, Ifrah N, Guillerm G, Contentin N, Bourhis JH, Yakoub Agha I, Bernard M, Cornillon J, Milpied N.

Haematologica. 2013 Sep;98(9):1467-75. doi: 10.3324/haematol.2012.080895. Epub 2013 Mar 28.

47.

Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.

Park S, Labopin M, Yakoub-Agha I, Delaunay J, Dhedin N, Deconinck E, Michallet M, Robin M, De Revel T, Bernard M, Vey N, Lioure B, Lapusan S, Tabrizi R, Bourhis JH, Huynh A, Beguin Y, Socié G, Dreyfus F, Fenaux P, Mohty M.

Eur J Haematol. 2013 May;90(5):355-64. doi: 10.1111/ejh.12073. Epub 2013 Mar 7.

48.

Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.

de Masson A, Bouaziz JD, Peffault de Latour R, Wittnebel S, Ribaud P, Rubio MT, Micol JB, Suarez F, Nguyen S, Dalle JH, Yakouben K, Robin M, Xhaard A, Adès L, Bourhis JH, Rybojad M, Bagot M, Socié G.

Blood. 2012 Dec 13;120(25):5089-90. doi: 10.1182/blood-2012-09-453928. No abstract available.

49.

Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy.

Coman T, Bachy E, Michallet M, Socié G, Uzunov M, Bourhis JH, Lapusan S, Brebion A, Vigouroux S, Maury S, François S, Huynh A, Lioure B, Yakoub-Agha I, Hermine O, Milpied N, Mohty M, Rubio MT.

Haematologica. 2013 May;98(5):776-83. doi: 10.3324/haematol.2012.069328. Epub 2012 Nov 9.

50.

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.

Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A, Etienne A, Andre P, Romagne F, Benson D, Dombret H, Olive D.

Blood. 2012 Nov 22;120(22):4317-23. doi: 10.1182/blood-2012-06-437558. Epub 2012 Sep 21.

Supplemental Content

Loading ...
Support Center